Antibodies against IL-17 and its receptor have been approved for the treatment of autoimmune diseases, but the potential side effects of blocking IL-17 are not well defined, particularly in the context of chronic kidney diseases [44]. The gene discussed is IL17A; the disease is autoimmune disease.